论文部分内容阅读
MTX(甲氨喋呤)常用于治疗银屑病、哮喘、类风湿性关节炎和癌症,当和作用机制相同的其它药物合用时可产生危险的相互作用。本文报道1例口服低剂量MTX和TMP—SMZ(甲氨苄啶—磺胺甲噁唑)产生罕见骨髓造血障碍的病症。患者,男,58岁,有类风湿性关节炎病史,现呈现前列腺炎症状。自1988年每周服用 MTX7.5mg,其关节炎已获有效治疗。全血细胞计数:血红蛋白133g/l,血细胞比容0.4,白细胞8.7×10~6/l,血小板197×10~9/l,患者尿培养有大肠杆菌生长,随TMP—SMZ
MTX (methotrexate), commonly used in the treatment of psoriasis, asthma, rheumatoid arthritis and cancer, can create dangerous interactions when used in combination with other drugs with the same mechanism of action. This article reports one case of low-dose oral MTX and TMP-SMZ (methotribin-sulfamethoxazole) that produces rare myeloid hematopoietic disorders. Patient, male, 58 years old, with a history of rheumatoid arthritis, present with prostatitis symptoms. Arthritis has been effectively treated with MTX 7.5 mg weekly since 1988. Whole blood count: Hemoglobin 133g / l, hematocrit 0.4, white blood cells 8.7 × 10 ~ 6 / l, platelets 197 × 10 ~ 9 / l, urine culture of patients with E. coli growth, with the TMP-SMZ